Spark Investment Management’s Concert Pharmaceuticals, Inc. CNCE Stock Holding History

Spark Investment Management’s Portfolio CNCE Stock Details CNCE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q2	–	Sell	-17,500	Closed	-$154K	–	325
2020 Q1	$154K	Buy	+17,500	New	+$173K	0.08%	249
2018 Q4	–	Sell	-56,297	Closed	-$835K	–	844
2018 Q3	$835K	Sell	56,297 -40,903	-42%	-$644K	0.05%	409
2018 Q2	$1.64M	Sell	97,200 -47,400	-33%	-$921K	0.1%	280
2018 Q1	$3.31M	Buy	+144,600	New	+$3.22M	0.21%	147
2016 Q4	–	Sell	-178,900	Closed	-$1.81M	–	913
2016 Q3	$1.81M	Sell	178,900 -94,500	-35%	-$1.03M	0.15%	215
2016 Q2	$3.07M	Sell	273,400 -30,100	-10%	-$383K	0.29%	106
2016 Q1	$4.14M	Sell	303,500 -7,700	-2%	-$111K	0.42%	50
2015 Q4	$5.9M	Buy	311,200 +4,900	+2%	+$106K	0.75%	13
2015 Q3	$5.74M	Buy	306,300 +134,900	+79%	+$2.29M	0.75%	13
2015 Q2	$2.55M	Buy	171,400 +69,100	+68%	+$1.05M	0.36%	76
2015 Q1	$1.55M	Sell	102,300 -8,200	-7%	-$114K	0.22%	149
2014 Q4	$1.47M	Buy	110,500 +43,700	+65%	+$564K	0.25%	127
2014 Q3	$839K	Buy	66,800 +51,900	+348%	+$503K	0.13%	233
2014 Q2	$150K	Sell	14,900 -3,800	-20%	-$36.7K	0.02%	525
2014 Q1	$251K	Buy	+18,700	New	+$264K	0.04%	483

Other funds holding CNCE

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

ISL

Ingalls & Snyder LLC New York $2.83B AUM 21.61% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

L1 Capital Melbourne VIC 3000, Australia $2.55B AUM 80.12% 1-Year Est. Return

SFM

Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return

Spark Investment Management's CNCE Position: Q2 2020 in Review

Spark Investment Management sold out of Concert Pharmaceuticals, Inc. (CNCE) in Q2 2020, closing a stake of 17,500 shares — an estimated $154K sold.

Spark Investment Management first reported a position in CNCE in Q1 2014 and held it in 15 quarters. The position peaked at $5.9M in Q4 2015. 91 funds tracked by Wall St. Rank hold CNCE as of Q2 2020.

Spark Investment Management reported no remaining Concert Pharmaceuticals, Inc. position as of Q2 2020 after selling out during the quarter.
Spark Investment Management sold 17,500 Concert Pharmaceuticals, Inc. shares in Q2 2020, an estimated $154K.
Spark Investment Management first reported a position in Concert Pharmaceuticals, Inc. in Q1 2014 and held it in 15 quarters.
Spark Investment Management's Concert Pharmaceuticals, Inc. position peaked at $5.9M in Q4 2015.
91 funds tracked by Wall St. Rank held Concert Pharmaceuticals, Inc. as of Q2 2020.

Based on Spark Investment Management's 13F filing for Q2 2020, filed 12 Aug 2020.